Streetly Allison, Clarke Mary, Downing Melanie, Farrar Lisa, Foo Ying, Hall Kate, Kemp Helena, Newbold Jane, Walsh Paul, Yates Jenny, Henthorn Joan
NHS Sickle Cell and Thalassaemia Screening Programme, Division of Health and Social Care Research, King's College London School of Medicine, 42 Weston Street, London, UK.
J Med Screen. 2008;15(1):9-13. doi: 10.1258/jms.2008.007063.
This paper reports early screening results from the newborn sickle cell disease screening programme recently implemented in England.
England. Screening is offered at 5-8 days of age as part of the existing bloodspot test and offered to all babies irrespective of ethnicity.
The laboratory methods recommended are high performance liquid chromatography (HPLC) and iso-electric focusing (IEF). Two methods of analysis must be applied to all screen positive results. The conditions screened for are:- Sickle cell anaemia (Hb SS), Hb SC disease, Hb S/beta-thalassaemia, Hb S/D(Punjab), Hb S/O(Arab), Hb S/HPFH. Carriers identified for the common haemoglobin variants are reported to parents and follow-up counselling is offered. A bespoke laboratory quality assurance programme has been established which has defined standards of satisfactory performance.
Provisional figures from the first seven months of screening (up to March 2004) 108,255 infants were screened gave a screen positive rate of 1:900 for these high prevalence areas and a carrier rate of 2.7%. Figures for 2004-2005 show about 250 significant screen positive results for sickle cell disorders and about 6,500 carriers were identified. The birth prevalence for screen positive results from 2004-05 is 1:1500. We estimate that when there is countrywide data, the national birth prevalence will be about 1:2000-1:2,500.
The results from the national newborn sickle cell screening programme in England-show that the sickle cell disorders are as common as cystic fibrosis (CF) in England, although the distribution of cases is concentrated in London and other urban areas. The findings and approach to implementation adopted in England may be of interest to other Western European countries with increasing rates of sickle cell disease who are considering such programmes and also to other developed countries.
本文报告了英国近期实施的新生儿镰状细胞病筛查项目的早期筛查结果。
英国。作为现有血斑检测的一部分,在婴儿5至8日龄时进行筛查,所有婴儿均可接受筛查,无论其种族如何。
推荐的实验室方法为高效液相色谱法(HPLC)和等电聚焦法(IEF)。所有筛查呈阳性的结果都必须采用两种分析方法。筛查的病症包括:镰状细胞贫血(Hb SS)、Hb SC病、Hb S/β地中海贫血、Hb S/D(旁遮普)、Hb S/O(阿拉伯)、Hb S/HPFH。已鉴定出常见血红蛋白变异体携带者的情况会告知其父母,并提供后续咨询服务。已建立了一个定制的实验室质量保证项目,该项目定义了令人满意的性能标准。
筛查前七个月(截至2004年3月)的初步数据显示,108,255名婴儿接受了筛查,这些高流行地区的筛查阳性率为1:900,携带者率为2.7%。2004 - 2005年的数据显示,镰状细胞病约有250例显著筛查阳性结果,约6500名携带者被鉴定出来。2004 - 05年筛查阳性结果的出生患病率为1:1500。我们估计,当有全国范围的数据时,全国出生患病率约为1:2000 - 1:2500。
英国全国新生儿镰状细胞筛查项目的结果表明,镰状细胞病在英国与囊性纤维化(CF)一样常见,尽管病例分布集中在伦敦和其他城市地区。英国的研究结果和实施方法可能会引起其他镰状细胞病发病率不断上升且正在考虑此类项目的西欧国家以及其他发达国家的兴趣。